Nuclear receptors as drug targets for metabolic disease

Advanced Drug Delivery Reviews

Volumn 62, Issue 13, 2010, Pages 1307-1315

  Schulman, Ira G ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Atherosclerosis; Cholesterol; Diabetes; Fatty acids; Metabolic disease; Nuclear receptors; Transcription

Indexed keywords

ATHEROSCLEROSIS; DIABETES; DRUG DISCOVERY; DRUG TARGETS; GENETIC NETWORKS; LIPID METABOLISMS; METABOLIC ACTIVITY; METABOLIC DISEASE; METABOLIC INTERMEDIATES; NUCLEAR HORMONE RECEPTOR; NUCLEAR RECEPTORS;

CHOLESTEROL; DISEASES; ENERGY UTILIZATION; FATTY ACIDS; MEDICAL PROBLEMS; PHYSIOLOGY; TRANSCRIPTION; TRANSCRIPTION FACTORS;

METABOLISM;

2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CELL NUCLEUS RECEPTOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; MBX 8025; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RALOXIFENE; ROSIGLITAZONE; UNCLASSIFIED DRUG; WAY 252623;

ADIPOGENESIS; ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; ENERGY METABOLISM; HEART FAILURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER METABOLISM; MACROPHAGE FUNCTION; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; DRUG DISCOVERY; ENERGY METABOLISM; HUMANS; LIGANDS; LIPID METABOLISM; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 78649325832     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.07.002     Document Type: Review

References (129)

1. Maglich J.M., Sluder A., Guan X., Shi Y., McKee D.D., Carrick K., Kamdar K., Willson T.M., Moore J.T. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol. 2001, 2. RESEARCH0029.
2. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
3. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81:1097-1142.
4. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96:23-43.
5. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
6. Edwards P.A., Kast H.R., Anisfeld A.M. BAREing it all. The adoption of lxr and fxr and their roles in lipid homeostasis. J. Lipid Res. 2002, 43:2-12.
7. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:4312-4317.
8. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:4318-4323.
9. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
10. Repa J.J., Mangelsdorf D.J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 1999, 10:557-563.
11. Y. Wang, N. Kumar, L.A. Solt, T.I. Richardson, L.M. Helvering, C. Crumbley, R.D. Garcia-Ordonez, K.R. Stayrook, X. Zhang, S. Novick, M.J. Chalmers, P.R. Griffin, and T.P. Burris, Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands, J Biol Chem 285 5013-5025.
12. Forman B.M., Ruan B., Chen J., Schroepfer G.J., Evans R.M. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:10588-10593.
13. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:266-271.
14. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR?. Nature 1996, 383:728-731.
15. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
16. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
17. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 1999, 103:1489-1498.
18. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:7473-7478.
19. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J.K., Gerard R.D., Burgess S.C., Hammer R.E., Mangelsdorf D.J., Kliewer S.A. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
20. Chakravarthy M.V., Lodhi I.J., Yin L., Malapaka R.R., Xu H.E., Turk J., Semenkovich C.F. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009, 138:476-488.
21. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 2006, 57:313-329.
22. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
23. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
24. Kraegen E.W., Cooney G.J. Free fatty acids and skeletal muscle insulin resistance. Curr. Opin. Lipidol. 2008, 19:235-241.
25. Medina-Gomez G., Gray S.L., Yetukuri L., Shimomura K., Virtue S., Campbell M., Curtis R.K., Jimenez-Linan M., Blount M., Yeo G.S., Lopez M., Seppanen-Laakso T., Ashcroft F.M., Oresic M., Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007, 3:e64.
26. He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E., Olefsky J.M., Evans R.M. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:15712-15717.
27. Tsai Y.S., Maeda N. PPARgamma: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc. Med. 2005, 15:81-85.
28. Colca J.R., Kletzien R.F. What has prevented the expansion of insulin sensitisers?. Expert Opin. Investig. Drugs 2006, 15:205-210.
29. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
30. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
31. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586.
32. Hollenberg N.K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. 2003, 115(Suppl 8A):111S-115S.
33. Karalliedde J., Buckingham R.E. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007, 30:741-753.
34. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11:861-866.
35. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 2006, 116:590-597.
36. Furnsinn C., Willson T.M., Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007, 50:8-17.
37. Chawla A., Lee C.H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., Evans R.M. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:1268-1273.
38. Oliver W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:5306-5311.
39. Oram J.F., Lawn R.M. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 2001, 42:1173-1179.
40. van der Veen J.N., Kruit J.K., Havinga R., Baller J.F., Chimini G., Lestavel S., Staels B., Groot P.H., Groen A.K., Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 2005, 46:526-534.
41. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., Evans R.M. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004, 2:e294.
42. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:15924-15929.
43. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., Evans R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
44. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., Evans R.M. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
45. Rockl K.S., Hirshman M.F., Brandauer J., Fujii N., Witters L.A., Goodyear L.J. Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes 2007, 56:2062-2069.
46. Billin A.N. PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin. Investig. Drugs 2008, 17:1465-1471.
47. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
48. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
49. Solinas G., Vilcu C., Neels J.G., Bandyopadhyay G.K., Luo J.L., Naugler W., Grivennikov S., Wynshaw-Boris A., Scadeng M., Olefsky J.M., Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
50. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
51. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
52. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 2007, 1771:926-935.
53. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
54. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
55. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Eagle A.R., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
56. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7:496-507.
57. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
58. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
59. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
60. Vats D., Mukundan L., Odegaard J.I., Zhang L., Smith K.L., Morel C.R., Wagner R.A., Greaves D.R., Murray P.J., Chawla A. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4:13-24.
61. Barish G.D., Atkins A.R., Downes M., Olson P., Chong L.W., Nelson M., Zou Y., Hwang H., Kang H., Curtiss L., Evans R.M., Lee C.H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Nat. Acad. Sci. U.S.A. 2008, 105:4271-4276.
62. Li A.C., Glass C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 2004, 45:2161-2173.
63. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8:1235-1242.
64. Marathe C., Bradley M.N., Hong C., Chao L., Wilpitz D., Salazar J., Tontonoz P. Preserved glucose tolerance in high fat diet-fed C57BL/6 mice transplanted with PPARgamma -/- PPARdelta -/-, PPARgamma delta -/- or LXRalpha beta -/- bone marrow. J. Lipid Res. 2009, 50:214-224.
65. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
66. Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 1994, 147:273-276.
67. Chen W., Chen G., Head D.L., Mangelsdorf D.J., Russell D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007, 5:73-79.
68. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275:28240-28245.
69. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
70. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:12097-12102.
71. Hayden M.R., Clee S.M., Brooks-Wilson A., Genest J., Attie A., Kastelein J.J. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr. Opin. Lipidol. 2000, 11:117-122.
72. Hobbs H.H., Rader D.J. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J. Clin. Invest. 1999, 104:1015-1017.
73. Aiello R.J., Brees D., Francone O.L. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler. Thromb. Vasc. Biol. 2003, 23:972-980.
74. Singaraja R.R., Fievet C., Castro G., James E.R., Hennuyer N., Clee S.M., Bissada N., Choy J.C., Fruchart J.C., McManus B.M., Staels B., Hayden M.R. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 2002, 110:35-42.
75. Joyce C.W., Amar M.J., Lambert G., Vaisman B.L., Paigen B., Najib-Fruchart J., Hoyt R.F., Neufeld E.D., Remaley A.T., Fredrickson D.S., Brewer H.B., Santamarina-Fojo S. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:407-412.
76. Wagner B.L., Valledor A.F., Shao G., Daige C.L., Bischoff E.D., Petrowski M., Jepsen K., Baek S.H., Heyman R.A., Rosenfeld M.G., Schulman I.G., Glass C.K. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell Biol. 2003, 23:5780-5789.
77. Kennedy M.A., Venkateswaran A., Tarr P.T., Xenarios I., Kudoh J., Shimizu N., Edwards P.A. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 2001, 276:39438-39447.
78. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:507-512.
79. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:9774-9779.
80. Schuster G.U., Parini P., Wang L., Alberti S., Steffensen K.R., Hansson G.K., Angelin B., Gustafsson J.A. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 2002, 106:1147-1153.
81. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., Wang X., Lusis A.J., Tontonoz P., Schulman I.G. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:11896-11901.
82. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003, 536:6-11.
83. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M., Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:7604-7609.
84. Levin N., Bischoff E.D., Daige C.L., Thomas D., Vu C.T., Heyman R.A., Tangirala R.K., Schulman I.G. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25:135-142.
85. Fowler A.J., Sheu M.Y., Schmuth M., Kao J., Fluhr J.W., Rhein L., Collins J.L., Willson T.M., Mangelsdorf D.J., Elias P.M., Feingold K.R. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 2003, 120:246-255.
86. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
87. Erbay E., Babaev V.R., Mayers J.R., Makowski L., Charles K.N., Snitow M.E., Fazio S., Wiest M.M., Watkins S.M., Linton M.F., Hotamisligil G.S. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 2009, 15:1383-1391.
88. Tall A.R., Yvan-Charvet L., Terasaka N., Pagler T., Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008, 7:365-375.
89. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.-M.A., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR?. Cell 1998, 93:693-704.
90. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 2002, 277:18793-18800.
91. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., Kwiterovich P., Shan B., Barnes R., Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
92. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
93. Groot P.H., Pearce N.J., Yates J.W., Stocker C., Sauermelch C., Doe C.P., Willette R.N., Olzinski A., Peters T., d'Epagnier D., Morasco K.O., Krawiec J.A., Webb C.L., Aravindhan K., Jucker B., Burgert M., Ma C., Marino J.P., Collins J.L., Macphee C.H., Thompson S.K., Jaye M. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 2005, 46:2182-2191.
94. de Villiers W.J., Smart E.J. Macrophage scavenger receptors and foam cell formation. J. Leukoc. Biol. 1999, 66:740-746.
95. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., Rhee J.S., Silverstein R., Hoff H.F., Freeman M.W. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 2002, 277:49982-49988.
96. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptor, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
97. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
98. Zhang Y., Repa J.J., Gauthier K., Mangelsdorf D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J. Biol. Chem. 2001, 276:43018-43024.
99. Wang Y., Kurdi-Haidar B., Oram J.F. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J. Lipid Res. 2004, 45:972-980.
100. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by LXRs. J. Biol. Chem. 2002, 277:11019-11025.
101. Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., Castrillo A., Wilpitz D.C., Mangelsdorf D.J., Collins J.L., Saez E., Tontonoz P. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:5419-5424.
102. Cao G., Liang Y., Broderick C.L., Oldham B.A., Beyer T.P., Schmidt R.J., Zhang Y., Stayrook K.R., Suen C., Otto K.A., Miller A.R., Dai J., Foxworthy P., Gao H., Ryan T.P., Jiang X.C., Burris T.P., Eacho P.I., Etgen G.J. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 2003, 278:1131-1136.
103. Gerin I., Dolinsky V.W., Shackman J.G., Kennedy R.T., Chiang S.H., Burant C.F., Steffensen K.R., Gustafsson J.A., MacDougald O.A. LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J. Biol. Chem. 2005, 280:23024-23031.
104. Green C.D., Jump D.B., Olson L.K. Elevated insulin secretion from liver X receptor-activated pancreatic beta-cells involves increased de novo lipid synthesis and triacylglyceride turnover. Endocrinology 2009, 150:2637-2645.
105. Ogihara T., Chuang J.C., Vestermark G.L., Garmey J.C., Ketchum R.J., Huang X., Brayman K.L., Thorner M.O., Repa J.J., Mirmira R.G., Evans-Molina C. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J Biol Chem. 2010, 285:5392-5404.
106. Brunham L.R., Kruit J.K., Pape T.D., Timmins J.M., Reuwer A.Q., Vasanji Z., Marsh B.J., Rodrigues B., Johnson J.D., Parks J.S., Verchere C.B., Hayden M.R. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13:340-347.
107. J.K. Kruit, P.H. Kremer, L. Dai, R. Tang, P. Ruddle, W. de Haan, L.R. Brunham, C.B. Verchere, and M.R. Hayden, Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice, Diabetologia 53 1110-1119.
108. Sturek J.M., Castle J.D., Trace A.P., Page L.C., Castle A.M., Evans-Molina C., Parks J.S., Mirmira R.G., Hedrick C.C. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J Clin Invest 2010, 120:2575-2589.
109. M. Vergeer, L.R. Brunham, J. Koetsveld, J.K. Kruit, C.B. Verchere, J.J. Kastelein, M.R. Hayden, and E.S. Stroes, Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction, Diabetes Care 33 869-874.
110. Muscat G.E., Wagner B.L., Hou J., Tangirala R.K., Bischoff E.D., Rohde P., Petrowski M., Li J., Shao G., Macondray G., Schulman I.G. Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J. Biol. Chem. 2002, 277:40722-40728.
111. Kalaany N.Y., Gauthier K.C., Zavacki A.M., Mammen P.P., Kitazume T., Peterson J.A., Horton J.D., Garry D.J., Bianco A.C., Mangelsdorf D.J. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 2005, 1:231-244.
112. Commerford S.R., Vargas L., Dorfman S.E., Mitro N., Rocheford E.C., Mak P.A., Li X., Kennedy P., Mullarkey T.L., Saez E. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol. Endocrinol. 2007, 21:3002-3012.
113. Luo Y., Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 2000, 105:513-520.
114. de Grooth G.J., Smilde T.J., Van Wissen S., Klerkx A.H., Zwinderman A.H., Fruchart J.C., Kastelein J.J., Stalenhoef A.F., Kuivenhoven J.A. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004, 173:261-267.
115. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., Mancuso J.P., Rader D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 2004, 350:1505-1515.
116. Klerkx A.H., de Grooth G.J., Zwinderman A.H., Jukema J.W., Kuivenhoven J.A., Kastelein J.J. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J. Clin. Invest. 2004, 34:21-28.
117. Alberti S., Schuster G., Parini P., Feltkamp D., Diczfalusy U., Rudling M., Angelin B., Bjorkhem I., Pettersson S., Gustafsson J.A. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 2001, 107:565-573.
118. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., Lusis A.J., Collins A., Hseuh W.A., Collins J.L., Tangirala R.K., Tontonoz P. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin. Invest. 2007, 117:2337-2346.
119. Lund E.G., Menke J.G., Sparrow C.P. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1169-1177.
120. Hoerer S., Schmid A., Heckel A., Budzinski R.M., Nar H. Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J. Mol. Biol. 2003, 334:853-861.
121. Farnegardh M., Bonn T., Sun S., Ljunggren J., Ahola H., Wilhelmsson A., Gustafsson J.A., Carlquist M. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem. 2003, 278:38821-38828.
122. Williams S., Bledsoe R.K., Collins J.L., Boggs S., Lambert M.H., Miller A.B., Moore J., McKee D.D., Moore L., Nichols J., Parks D., Watson M., Wisely B., Willson T.M. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 2003, 278:27138-27143.
123. Svensson S., Ostberg T., Jacobsson M., Norstrom C., Stefansson K., Hallen D., Johansson I.C., Zachrisson K., Ogg D., Jendeberg L. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. Embo J. 2003, 22:4625-4633.
124. Quinet E.M., Basso M.D., Halpern A.R., Yates D.W., Steffan R.J., Clerin V., Resmini C., Keith J.C., Berrodin T.J., Feingold I., Zhong W., Hartman H.B., Evans M.J., Gardell S.J., DiBlasio-Smith E., Mounts W.M., LaVallie E.R., Wrobel J., Nambi P., Vlasuk G.P. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. 2009, 50:2358-2370.
125. Wrobel J., Steffan R., Bowen S.M., Magolda R., Matelan E., Unwalla R., Basso M., Clerin V., Gardell S.J., Nambi P., Quinet E., Reminick J.I., Vlasuk G.P., Wang S., Feingold I., Huselton C., Bonn T., Farnegardh M., Hansson T., Nilsson A.G., Wilhelmsson A., Zamaratski E., Evans M.J. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem. 2008, 51:7161-7168.
126. McDonnell D.P., Connor C.E., Wijayaratne A., Chang C.Y., Norris J.D. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog. Horm. Res. 2002, 57:295-316.
127. Greschik H., Moras D. Structure-activity relationship of nuclear receptor-ligand interactions. Curr. Top. Med. Chem. 2003, 3:1573-1599.
128. Steinmetz A.C., Renaud J.P., Moras D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 2001, 30:329-359.
129. Schulman I.G., Heyman R.A. The flip side: identifying small molecule regulators of nuclear receptors. Chem. Biol. 2004, 11:639-646.